Media Coverage
Read how Vistagen’s intention to revolutionize mental health medicine is causing a buzz in the media.
The Future of Healthcare: “Let’s focus on a new generation of treatment options for major depressive disorder, social anxiety disorder and suicidal ideation.”
Ketamine-Like Compound Offers New Hope as a Potential Antidepressant and Non-opioid Painkiller
FDA clears J&J's esketamine in treatment-resistant depression, with restrictions as per REMS
J&J's ketamine-based drug drives sea change for new depression treatments
Seeking a Cure: VistaGen Therapeutics' Potential Anti-Depression Drug
FDA approves Spravato nasal spray for depression
BioSpace's Global Biopharma Roundup: February 21
J&J nears FDA approval for landmark depression drug to replace ketamine treatments
Can We Treat Mood Disorders with Pharmacological Therapeutics?
